Cytogen Inc Cash Flow-to-Debt Ratio
Cytogen Inc cash flow-to-debt ratio. Cytogen Inc (217330) has a Cash Flow-to-Debt Ratio of -0.08x as of December 2025, meaning its operating cash flow of ₩-2.13 Billion could theoretically repay 0% of its total liabilities (₩26.25 Billion) in one year. See 217330 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cytogen Inc (2014–2025)
Cash flow-to-debt ratio of Cytogen Inc from 2014 to 2025. Historical debt coverage capacity for Cytogen Inc across 12 annual periods. Also explore 217330 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Cytogen Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Cytogen Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Cytogen Inc. For the full cash flow conversion analysis, see 217330 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.26x | ₩-6.95 Billion | ₩26.25 Billion | ▲ +33.6% |
| 2024 | -0.40x | ₩-9.53 Billion | ₩23.89 Billion | ▼ -10.8% |
| 2023 | -0.36x | ₩-7.59 Billion | ₩21.09 Billion | ▼ -100.7% |
| 2022 | -0.18x | ₩-6.38 Billion | ₩35.56 Billion | ▼ -11.5% |
| 2021 | -0.16x | ₩-5.23 Billion | ₩32.52 Billion | ▲ +64.1% |
| 2020 | -0.45x | ₩-4.47 Billion | ₩9.97 Billion | ▲ +76.1% |
| 2019 | -1.88x | ₩-3.37 Billion | ₩1.80 Billion | ▲ +51.8% |
| 2018 | -3.89x | ₩-2.77 Billion | ₩711.51 Million | ▼ -69.3% |
| 2017 | -2.30x | ₩-2.18 Billion | ₩947.50 Million | ▼ -346.3% |
| 2016 | -0.52x | ₩-2.36 Billion | ₩4.59 Billion | ▲ +59.5% |
| 2015 | -1.27x | ₩-2.03 Billion | ₩1.60 Billion | ▼ -94.4% |
| 2014 | -0.65x | ₩-1.03 Billion | ₩1.57 Billion | — |